Eisai Clinical Trials
Study Overview
E7080
lenvatinib
NCT00784303, 2007-005933-12
Nov 2008 - Mar 2019
Thyroid Cancer
1. Objective Response Rate (ORR) [Time Frame: From date of treatment start until disease progression, development of unacceptable toxicity, withdrawal of consent, participant's choice to stop study treatment, or up to data cutoff date 11 April 2011, for up to approximately 2 years 5 months]
2. Plasma Pharmacokinetics (PK): Steady State Area Under the Plasma Concentration Curve (AUC) [Time Frame: Cycle 1 Day 1 (predose and at 0.5 and 2 hours postdose), Cycle 1 Day 8 (predose), Cycle 2 Day 1 (predose and at 0.5 and 2 hours postdose), and Cycle 3 Day 1 (predose and at 2 hours postdose) (Cycle length= 28 days)]
-
Males and females 18 Years to 99 Years (Adult, Older Adult)
-
Completed -
Phase 2
Australia, France, Italy, Poland, United Kingdom, United States See moreData Sharing
ClinicalStudyDataRequest.com (CSDR) is a multi sponsor site through which qualified researchers who wish to access clinical trial data and associated information in order to conduct further research can submit their research proposal or enquiry.
CSDR Sharing is available for this study.
CSDR Availability Clinical Trial Data Redacted documents may be available upon request for this study.
Document type Availability Protocol SAP Sample CRF Full CSR